Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Craniopharyngioma 2COVID-19 2Burkitt Lymphoma 2Arthritis, Rheumatoid 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Respiratory Tract Infections 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Cyclophosphamide 220Rituximab 189fludarabine phosphate 169fludarabine 102Peripheral Blood Stem Cell Transplantation 100Mycophenolic Acid 94Whole-Body Irradiation 81Tacrolimus 72Filgrastim 69Cyclosporine 67Lenalidomide 66ibrutinib 63Busulfan 61Melphalan 58Antilymphocyte Serum 57Radiotherapy 52venetoclax 48Etoposide 47obinutuzumab 42Bendamustine Hydrochloride 42Alemtuzumab 41Methotrexate 39ofatumumab 28sargramostim 27Granulocyte Colony-Stimulating Factor 26Cytarabine 26Cord Blood Stem Cell Transplantation 26acalabrutinib 25Stem Cell Transplantation 24Specimen Handling 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphocytic, Chronic, B-Cell × tocilizumab × Clear all
NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Dana-Farber Cancer Institute

Phase 2 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡